Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14386089 | 1.00 | NPC1 (0.51) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL12235253 | 1.00 | NPC1 (0.51) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL920229 | 0.98 | NPC1 (0.50) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL7284168 | 0.90 | NPC1 (0.50) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL7269210 | 0.90 | NPC1 (0.50) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL7276887 | 0.90 | NPC1 (0.50) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL6002636 | 0.89 | NPC1 (0.49) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL4440609 | 0.87 | NPC1 (0.57) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL2850953 | 0.87 | NPC1 (0.48) | NPC1RAB9AKMT2AHTR1ACES2 | |
| SCHEMBL28938264 | 0.87 | NPC1 (0.48) | NPC1RAB9AKMT2AHTR1ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5223593-A | Low optical loss; dihydroperfluoroacrylate polymers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-06-29 | — | — | US | claimed |
| EP-2709666-B1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS NV (NL) | 2021-07-14 | — | — | EP | disclosed |
| US-10004810-B2 | Bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2018-06-26 | — | — | US | disclosed |
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2017-05-25 | — | — | US | disclosed |
| US-9421274-B2 | Bio-orthogonal drug activation | KONINKLIJKE PHILIPS N.V. (NL) | 2016-08-23 | — | — | US | disclosed |
| EP-2709666-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | Koninklijke Philips N.V. (NL) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012156918-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-11-22 | — | — | WO | disclosed |
| US-7888080-B2 | enzymically reducing the corresponding ketones to prepare alkanols; preparing (1S)-3-methylamino-1-(2-thienyl)propan-1-ol and (1S)-3-chloro-1-(2-thienyl)propan-1-ol from 3-methylamino-1-(2-thienyl)propanone and 3-chloro-1-(2-thienyl)propanone; dehydrogenase | BASF SE (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7790436-B2 | Method for production of (1S)-3-chloro-1-(2-thienyl)-propan-1-ol using alcohol dehydrogenase from thermoanaerobacter | BASF SE (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7785847-B2 | Method for producing optically active alcohols from alkanones using a dehydrogenase of azoarcus | BASF SE (DE) | 2010-08-31 | — | — | US | disclosed |
| US-6284840-B1 | MIXING AT LEAST ONE RUBBER AND AT LEAST ONE THERMOPLASTIC OR THERMOPLASTIC ELASTOMER AT A FIRST TEMPERATURE; COOLING THE MIXTURE TO A SECOND TEMPERATURE; HEATING THE SECOND MIXTURE WITH A FREE-RADICAL INITIATOR TO FACILITATE CROSSLINKING. | ACUSHNET COMPANY | 2001-09-04 | — | — | US | disclosed |
| US-6245862-B1 | GOLF BALL COMPRISING COVER AND CORE LAYER, WHEREIN COVER IS FORMED OF COMPOSITION CONSISTING ESSENTIALLY OF AT LEAST ONE IONOMER FORMED FROM THERMOPLASTIC POLYMER HAVING SULFONATE AND/OR PHOSPHONATE MOIETIES | ACUSHNET COMPANY | 2001-06-12 | — | — | US | disclosed |
| WO-2000059583-A1 | GOLF BALL CORE COMPOSITIONS CONTAINING HIGH VICAT SOFTENING TEMPERATURE, RESILIENT THERMOPLASTIC MATERIALS | ACUSHNET COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6001930-A | Golf ball forming compositions comprising polyamide blended with sulfonated or phosphonated polymers | ACUSHNET COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999061113-A1 | GOLF BALLS COMPRISING SULFONATED OR PHOSPHONATED IONOMERS | ACUSHNET COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5981654-A | SINGLE LAYER COVER AND A SINGLE LAYER CORE, WHEREIN THE COVER COMPRISES BLEND OF ONE NONIONOMER POLYMER AND ONE POLYAMIDE POLYMER; RESILIENCE, DISTANCE | ACUSHNET COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1999032196-A1 | GOLF BALL FORMING COMPOSITIONS COMPRISING POLYAMIDE BLENDED WITH SULFONATED OR PHOSPHONATED POLYMERS | ACUSHNET COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998052652-A1 | GOLF BALL FORMING COMPOSITIONS COMPRISING POLYAMIDE | ACUSHNET COMPANY (US) | 1998-11-26 | — | — | WO | disclosed |
| EP-0599906-A1 | HERBICIDES CONTAINING 3-AMINOBENZO B]THIOPHENES AS AN ANTIDOTE. | BASF AG (DE) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993004057-A2 | HERBICIDES CONTAINING 3-AMINOBENZO[B]THIOPHENES AS AN ANTIDOTE | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143840-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | JMJD7, KIT, PAICS | NPC1 4317/4885RAB9A 1583/4885KMT2A 949/4885 |
| US-10004810-B2 | Bio-orthogonal drug activation | JMJD7, KIT, PAICS | NPC1 4317/4885RAB9A 1583/4885KMT2A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.